Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

KRAS-Mutant Non–Small Cell Lung Cancer: Recent Progress

Version 1 : Received: 24 November 2021 / Approved: 26 November 2021 / Online: 26 November 2021 (11:34:27 CET)

How to cite: shu, C.; Liu, Y.; Zhou, C. KRAS-Mutant Non–Small Cell Lung Cancer: Recent Progress. Preprints 2021, 2021110504. https://doi.org/10.20944/preprints202111.0504.v1 shu, C.; Liu, Y.; Zhou, C. KRAS-Mutant Non–Small Cell Lung Cancer: Recent Progress. Preprints 2021, 2021110504. https://doi.org/10.20944/preprints202111.0504.v1

Abstract

The KRAS mutant population has been undruggable for 40 years. G12C inhibitors and immunotherapy are the beginning of success. It is necessary to summarize the successful experience of the existing treatment model and explore the direction of the next treatment. In this review, we discuss the latest developments in targeted therapy and immunotherapy for KRAS-mutation NSCLC, aiming to provide direction or enlightenment for future treatment strategies.

Keywords

NSCLC 1; KRAS G12C mutation 2; targeted therapy 3; immunotherapy 4

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.